Drugs / TEZ/IVA
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT03768089 Background | Mar 2018 → May 2019 | cystic fibrosis | Vertex Pharmaceuticals Incorporated | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TEZ/IVA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03768089 ↗ |
| Route | Oral | “Fixed-dose combination tablet for oral administration.” NCT03768089 ↗ |